Time New York: Tue 26 Mar 01:56 am  |  Save 15% on H&R Block Online


Why Chemours Company (CC) Could Beat Earnings Estimates Again


Looking for a stock that might be in a good position to beat earnings at its next report? Consider The Chemours Company CC, a firm in the Chemical – Diversified industry, which could be a great candidate for another beat.

This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. In fact, in these reports, CC has beaten estimates by at least 10% in both cases, suggesting it has a nice short-term history of crushing expectations.

Earnings in Focus

Two quarters ago, CC expected to post earnings of $1.01 per share, while it actually produced earnings of $1.12 per share, a beat of 10.9%. Meanwhile, for the most recent quarter, the company looked to deliver earnings of 95 cents per share, when it actually delivered earnings of $1.19 per share instead, representing 25.3% positive surprise.

Chemours Company (The) Price and EPS Surprise

Chemours Company (The) Price and EPS Surprise | Chemours Company (The) Quote

Thanks in part to this history, recent estimates have been moving higher for Chemours Company. In fact, the Earnings ESP for CC is positive, which is a great sign of a coming beat.

After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company’s earnings prospects. This is the case for CC, as the firm currently has a Zacks Earnings ESP of +2.72%, so another beat could be around the corner.

This is particularly true when you consider that CC has a great Zacks Rank #1 (Strong Buy) which can be a harbinger of outperformance and a signal for a strong earnings profile. You can see the complete list of today’s Zacks #1 Rank stocks here.

When you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70%, so it seems pretty likely that CC could see another beat at its next report, especially if recent trends are any guide.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.